Fig. 5

Reduction of cell viability of primary leukemic ALL and AML cells treated with talazoparib in combination with INO and GO, respectively. A Cell viability analysis and Zero Interaction Potency (ZIP) score of bone marrow or peripheral blood cells from adult ALL patients (n = 5) treated with escalating concentrations of talazoparib and INO for 72 h. In the histograms, viable cells are shown as a percentage of the control cell (DMSO-treated), while the two-dimensional synergy map shows the ZIP score for each drug combination. B Cell viability analysis and ZIP scores of bone marrow or peripheral blood cells from adult AML patients (n = 5) treated with escalating concentrations of talazoparib and GO for 72 h. In the histograms, viable cells are shown as a percentage of the control cell (DMSO-treated), while the two-dimensional synergy map shows the ZIP score for each drug combination. The patient-specific drug concentrations are reported in the figure axes